
-
vTv Therapeutics NASDAQ:VTVT vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing oral, small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by programs for the treatment of type 1 diabetes and inflammatory disorders, including psoriasis. vTv's development partners are pursuing additional indications in type 2 diabetes, chronic obstructive pulmonary disease (COPD), renal disease, and primary mitochondrial myopathy.
Location: 3980 Premier Dr, Suite 310, North Carolina, 27265, US | Website: www.vtvtherapeutics.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
23.51M
Cash
36.83M
Avg Qtr Burn
-6.327M
Short % of Float
2.14%
Insider Ownership
36.34%
Institutional Own.
21.32%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Cadisegliatin (TTP399) Details Type 1 diabetes, Diabetes | Phase 3 Update | |
HPP737 Details Psoriasis, Skin disease/disorder | Phase 2 Update | |
Cadisegliatin (TTP399) Details Diabetes, Type 2 diabetes | Phase 2 Initiation | |
TTP273 (Oral GLP-1R) Details Diabetes, Type 2 diabetes, Cystic fibrosis | Phase 1/2 Update | |
TTP488 (Azeliragon) (RAGE) Details Frontotemporal dementia with C9orf72 mutation, Dementia, Alzheimer's disease, Neurological disorder | Failed Discontinued |